Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KX01 Ointment in Plaque Type Psoriasis
NCT05522816Phase 1Completed
- Sponsor
- PharmaEssentia
- Start
- Oct 2015
- Primary completion
- Mar 2021
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of tirbanibulin in plaque psoriasis (6 arms), sponsored by PharmaEssentia. Primary endpoints: Adverse event at Day 29, Local tolerability score at Day 29 and 5 more. Started Oct 2015; status: completed.
02
Drugs
tirbanibulin
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05522816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05522816.